View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAntibe Therapeutics 배당 및 자사주 매입배당 기준 점검 0/6Antibe Therapeutics 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률0%자사주 매입 수익률총 주주 수익률0%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 19Taro Pharmaceuticals Inc. completed the acquisition of Antibe Therapeutics Inc. for CAD 4.5 million.Taro Pharmaceuticals Inc. agreed to acquire Antibe Therapeutics Inc. on January 15, 2025. A cash consideration will be paid by Taro Pharmaceuticals Inc. The transaction is subject to subject to court approval. The expected completion of the transaction is March 7, 2025. Taro Pharmaceuticals Inc. completed the acquisition of Antibe Therapeutics Inc. for CAD 4.5 million on March 17, 2025.공시 • Jan 16Taro Pharmaceuticals Inc. agreed to acquire Antibe Therapeutics Inc.Taro Pharmaceuticals Inc. agreed to acquire Antibe Therapeutics Inc. on January 16, 2025. A cash consideration will be paid by Taro Pharmaceuticals Inc. The transaction is subject to subject to court approval. The expected completion of the transaction is March 7, 2025.공시 • Apr 24Antibe Therapeutics Inc. Announces Board ResignationsAntibe Therapeutics Inc. announced that Roderick Flower, Robert Hoffman, Dan Legault, Walt Macnee and Yung Wu have resigned from Antibe’s Board of Directors.공시 • Apr 09Antibe Therapeutics Inc. Announces Board ResignationsAntibe Therapeutics Inc. announced that Amal Khouri and Jennifer McNealey have resigned from its Board of Directors effective April 8, 2024.공시 • Apr 02+ 2 more updatesNuance Pharma Limited Commences Legal Action Against Antibe Therapeutics Inc. in the Ontario Superior Court Legal ActionAntibe Therapeutics Inc. announced that Nuance Pharma Limited has commenced legal action in the Ontario Superior Court of Justice to seek recognition of and enforce the arbitration award in Ontario previously announced by Antibe in its press release of March 4, 2024. Nuance Pharma is seeking the appointment of a receiver as part of its relief; a hearing date has not been set.공시 • Nov 10Antibe Therapeutics Inc. Reports PK Results of First Clinical Study of Otenaproxesul’s New FormulationAntibe Therapeutics Inc. announced the PK results of the pharmacokinetic/pharmacodynamic ("PK/PD") study of otenaproxesul's faster-absorbing formulation. The study was designed to confirm the drug's safety and inform the selection of treatment regimens for the upcoming Phase II trial, on track to launch in calendar First Quarter 2024. The PK/PD study involved 36 healthy volunteers, randomized across three treatment arms: a single high dose and two five-day regimens of o tenaproxesul. Subjects remained in-clinic for the duration of their treatment. As previously reported, all subjects completed the study with no clinically significant, drug-related adverse events and no increase in liver enzymes. In line with preclinical data and DILIsym liver safety modeling, the study confirmed the new formulation's linear, dose-proportional PK, with substantially lower doses needed to achieve target plasma levels compared to the original formulation. More rapid elimination was also observed, expanding the drug's safety envelope. These data provide the basis for selecting treatment regimens to achieve the pain relief expectations of patients, doctors and regulators. They also advance Antibe's exploration of potential treatment regimens for chronic pain.공시 • Nov 02Antibe Completes First Clinical Study of Otenaproxesul’s New FormulationAntibe Therapeutics Inc. announced the completion of the pharmacokinetic/pharmacodynamic (“PK/PD”) study of otenaproxesul’s faster-absorbing formulation for acute pain. The study was designed to confirm the drug’ssafety and inform treatment regimens for the upcoming Phase II trial, on track to launch in calendar First Quarter 2024. The PK/PD study involved 36 healthy volunteers randomized across three treatment arms: a single high dose and two five-day regimens of otenaproxesul. The five-day regimens were chosen to correspond to regimens envisaged for the upcoming Phase II trial. Subjects remained in-clinic for the duration of their treatment. All subjectscompleted the study with no clinically significant, drug-related adverse events and no elevation in liver enzymes during treatment or in post-treatment follow up.공시 • Oct 19Antibe Initiates First Clinical Study of Otenaproxesul’s New FormulationAntibe Therapeutics Inc. announce the initiation of the pharmacokinetic/pharmacodynamic (“PK/PD”) study of otenaproxesul’s faster-absorbing formulation for acute pain. The study is designed to inform the doses and confirm safety in preparation for the Phase II trial, on track to launch in calendar First Quarter 2024. The PK/PD study will involve 36 healthy volunteers randomized across three treatment arms: a single high dose and two five-day regimens of otenaproxesul. Subjects will remain in-clinic for the duration of their treatment. Expected in November, the study data will also advance Antibe’s exploration of potential treatment regimens for chronic pain.공시 • Sep 29Antibe Therapeutics Inc. Receives Approval to Initiate PK/PD Study of OtenaproxesulAntibe Therapeutics Inc. announced Health Canada's approval to initiate the pharmacokinetic/pharmacodynamic study of otenaproxesul's faster-absorbing formulation for acute pain. Set to commence in October, the purpose of the study is to inform the doses for the Phase II trial.공시 • Jul 01Antibe Therapeutics Inc., Annual General Meeting, Sep 08, 2023Antibe Therapeutics Inc., Annual General Meeting, Sep 08, 2023. Location: Toronto, ON Toronto Canada공시 • Feb 16Antibe Therapeutics Inc. Announces Retirement of Dr. John L. Wallace from the Board of DirectorsAntibe Therapeutics Inc. announced that its founder, Dr. John L. Wallace, has decided to retire from the Board of Directors. Dr. Wallace will remain a corporate Vice Chair, enabling the company to continue to benefit from his wisdom and expertise.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 ATBP.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: ATBP.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Antibe Therapeutics 배당 수익률 vs 시장ATBP.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ATBP.F)n/a시장 하위 25% (US)1.3%시장 상위 25% (US)4.1%업계 평균 (Pharmaceuticals)1.9%분석가 예측 (ATBP.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ATBP.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ATBP.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ATBP.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: ATBP.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/05/28 13:09종가2024/04/08 00:00수익2023/12/31연간 수익2023/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Antibe Therapeutics Inc.는 7명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Sally YanchusBrookline Capital MarketsTania Armstrong-WhitworthCanaccord GenuityDouglas LoeLeede Financial Inc4명의 분석가 더 보기
공시 • Mar 19Taro Pharmaceuticals Inc. completed the acquisition of Antibe Therapeutics Inc. for CAD 4.5 million.Taro Pharmaceuticals Inc. agreed to acquire Antibe Therapeutics Inc. on January 15, 2025. A cash consideration will be paid by Taro Pharmaceuticals Inc. The transaction is subject to subject to court approval. The expected completion of the transaction is March 7, 2025. Taro Pharmaceuticals Inc. completed the acquisition of Antibe Therapeutics Inc. for CAD 4.5 million on March 17, 2025.
공시 • Jan 16Taro Pharmaceuticals Inc. agreed to acquire Antibe Therapeutics Inc.Taro Pharmaceuticals Inc. agreed to acquire Antibe Therapeutics Inc. on January 16, 2025. A cash consideration will be paid by Taro Pharmaceuticals Inc. The transaction is subject to subject to court approval. The expected completion of the transaction is March 7, 2025.
공시 • Apr 24Antibe Therapeutics Inc. Announces Board ResignationsAntibe Therapeutics Inc. announced that Roderick Flower, Robert Hoffman, Dan Legault, Walt Macnee and Yung Wu have resigned from Antibe’s Board of Directors.
공시 • Apr 09Antibe Therapeutics Inc. Announces Board ResignationsAntibe Therapeutics Inc. announced that Amal Khouri and Jennifer McNealey have resigned from its Board of Directors effective April 8, 2024.
공시 • Apr 02+ 2 more updatesNuance Pharma Limited Commences Legal Action Against Antibe Therapeutics Inc. in the Ontario Superior Court Legal ActionAntibe Therapeutics Inc. announced that Nuance Pharma Limited has commenced legal action in the Ontario Superior Court of Justice to seek recognition of and enforce the arbitration award in Ontario previously announced by Antibe in its press release of March 4, 2024. Nuance Pharma is seeking the appointment of a receiver as part of its relief; a hearing date has not been set.
공시 • Nov 10Antibe Therapeutics Inc. Reports PK Results of First Clinical Study of Otenaproxesul’s New FormulationAntibe Therapeutics Inc. announced the PK results of the pharmacokinetic/pharmacodynamic ("PK/PD") study of otenaproxesul's faster-absorbing formulation. The study was designed to confirm the drug's safety and inform the selection of treatment regimens for the upcoming Phase II trial, on track to launch in calendar First Quarter 2024. The PK/PD study involved 36 healthy volunteers, randomized across three treatment arms: a single high dose and two five-day regimens of o tenaproxesul. Subjects remained in-clinic for the duration of their treatment. As previously reported, all subjects completed the study with no clinically significant, drug-related adverse events and no increase in liver enzymes. In line with preclinical data and DILIsym liver safety modeling, the study confirmed the new formulation's linear, dose-proportional PK, with substantially lower doses needed to achieve target plasma levels compared to the original formulation. More rapid elimination was also observed, expanding the drug's safety envelope. These data provide the basis for selecting treatment regimens to achieve the pain relief expectations of patients, doctors and regulators. They also advance Antibe's exploration of potential treatment regimens for chronic pain.
공시 • Nov 02Antibe Completes First Clinical Study of Otenaproxesul’s New FormulationAntibe Therapeutics Inc. announced the completion of the pharmacokinetic/pharmacodynamic (“PK/PD”) study of otenaproxesul’s faster-absorbing formulation for acute pain. The study was designed to confirm the drug’ssafety and inform treatment regimens for the upcoming Phase II trial, on track to launch in calendar First Quarter 2024. The PK/PD study involved 36 healthy volunteers randomized across three treatment arms: a single high dose and two five-day regimens of otenaproxesul. The five-day regimens were chosen to correspond to regimens envisaged for the upcoming Phase II trial. Subjects remained in-clinic for the duration of their treatment. All subjectscompleted the study with no clinically significant, drug-related adverse events and no elevation in liver enzymes during treatment or in post-treatment follow up.
공시 • Oct 19Antibe Initiates First Clinical Study of Otenaproxesul’s New FormulationAntibe Therapeutics Inc. announce the initiation of the pharmacokinetic/pharmacodynamic (“PK/PD”) study of otenaproxesul’s faster-absorbing formulation for acute pain. The study is designed to inform the doses and confirm safety in preparation for the Phase II trial, on track to launch in calendar First Quarter 2024. The PK/PD study will involve 36 healthy volunteers randomized across three treatment arms: a single high dose and two five-day regimens of otenaproxesul. Subjects will remain in-clinic for the duration of their treatment. Expected in November, the study data will also advance Antibe’s exploration of potential treatment regimens for chronic pain.
공시 • Sep 29Antibe Therapeutics Inc. Receives Approval to Initiate PK/PD Study of OtenaproxesulAntibe Therapeutics Inc. announced Health Canada's approval to initiate the pharmacokinetic/pharmacodynamic study of otenaproxesul's faster-absorbing formulation for acute pain. Set to commence in October, the purpose of the study is to inform the doses for the Phase II trial.
공시 • Jul 01Antibe Therapeutics Inc., Annual General Meeting, Sep 08, 2023Antibe Therapeutics Inc., Annual General Meeting, Sep 08, 2023. Location: Toronto, ON Toronto Canada
공시 • Feb 16Antibe Therapeutics Inc. Announces Retirement of Dr. John L. Wallace from the Board of DirectorsAntibe Therapeutics Inc. announced that its founder, Dr. John L. Wallace, has decided to retire from the Board of Directors. Dr. Wallace will remain a corporate Vice Chair, enabling the company to continue to benefit from his wisdom and expertise.